Medication info
Crelor Tablet 5 mg (Rosuvastatin Calcium)

Crelor Tablet 5 mg (Rosuvastatin Calcium)

Prescription medicationTablet
Ingredient · strength
Rosuvastatin Calcium›5.2mg / 1 tablet
Manufacturer / importer
Dasan Pharmaceutical Co., Ltd.
Appearance
Yellow round film-coated tablet
Packaging
For domestic use - 30 tablets/bottle
Approval status
Active

MFDS item code 201903850 · Approved 2019.06.13 · Insurance code 678601370

Summary

Main use
Treatment of dyslipidemia, inhibition of atherosclerosis progression, reduction of cardiovascular disease risk
Who uses it
Adults · Children
Adult dosage
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medication and should continue it throughout the treatment period. This medication may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which is sufficient to control the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to the LDL cholesterol level, treatment goal, and patient response, and may be increased up to a maximum of 20 mg daily. 3. Older adults: No dose adjustment is required. 4. Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering this medication at 20mg to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Assessment of renal function should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medication to patients with active liver disease. 6. Race: Because systemic exposure to this medication is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this medication is contraindicated in some of these patients.
Children's dosage
2. Pediatric patients with heterozygous familial hypercholesterolemia (age 10 to 17 years): The usual dose range is 5 mg to 20 mg once daily. (There are no clinical data on doses greater than 20 mg in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. Safety and efficacy have not been established in children under 10 years of age.

Ingredients

Manufacturer
Dasan Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of dyslipidemia, inhibition of atherosclerosis progression, reduction of cardiovascular disease risk

  • Primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • primary dysbetalipoproteinemia
  • elevated high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol levels
  • smoking
  • family history of early coronary artery disease
View approved original text

This medication is primarily used to treat patients with primary hypercholesterolemia or mixed dyslipidemia that are not controlled by diet and exercise. It also serves as an adjunct to diet or other lipid-lowering therapies for patients with homozygous familial hypercholesterolemia. This drug is effective in lowering total cholesterol and LDL cholesterol levels to slow the progression of atherosclerosis. Additionally, it is used to reduce cholesterol levels in pediatric patients aged 10 to 17 years with heterozygous familial hypercholesterolemia. It is also useful as an adjunct to diet for patients with primary dysbetalipoproteinemia. Furthermore, it helps in reducing the risks of stroke, myocardial infarction, and vascular revascularization in patients at high risk for cardiovascular disease. Therefore, this medication is used to improve various diseases and risk factors associated with hypercholesterolemia.

Dosage and Administration

Adult dosage

1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medication and should continue it throughout the treatment period. This medication may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which is sufficient to control the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to the LDL cholesterol level, treatment goal, and patient response, and may be increased up to a maximum of 20 mg daily. 3. Older adults: No dose adjustment is required. 4. Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering this medication at 20mg to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Assessment of renal function should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medication to patients with active liver disease. 6. Race: Because systemic exposure to this medication is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this medication is contraindicated in some of these patients.

Children's dosage

2. Pediatric patients with heterozygous familial hypercholesterolemia (age 10 to 17 years): The usual dose range is 5 mg to 20 mg once daily. (There are no clinical data on doses greater than 20 mg in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. Safety and efficacy have not been established in children under 10 years of age.

Precautions

This medication should not be used in patients with certain diseases or conditions. For example, it is contraindicated in patients who have had allergic reactions to this drug, those with severe liver dysfunction, or those with muscle disorders. Additionally, it should not be used in patients with severely impaired renal function, pregnant or breastfeeding women, or fertile women who are not practicing appropriate contraception. This medication contains lactose, and it should not be administered to patients with lactose intolerance or related genetic disorders. When using this medication, regular checks of liver function and muscle condition should be conducted, especially in patients who consume significant amounts of alcohol or have a history of liver disease. If symptoms such as muscle pain, weakness, fatigue, or fever occur, the doctor should be informed immediately, and the medication may need to be discontinued. Patients at high risk of serious muscle disorders, such as those with moderate to severe renal impairment, hypothyroidism, or a family history of muscle disease, should be particularly cautious when using this medication and should have muscle enzyme levels monitored before and after treatment. This medication may increase the concentration of other specific drugs in the bloodstream when used concomitantly, raising the risk of side effects. Therefore, it is essential to consult a physician or pharmacist if other medications are being taken. Pregnant or breastfeeding individuals should avoid this medication due to potential risks to the fetus or infant, and women planning to become pregnant should use appropriate contraception. In case of overdose, there is no specific antidote, and treatment should be symptomatic, with monitoring of liver function and muscle enzymes. Rarely, this medication may cause severe skin reactions, liver damage, neurological abnormalities, or myopathy. Therefore, if any unusual symptoms occur, immediate medical attention should be sought. Caution is necessary as dizziness may occur during driving or operating machinery. Patients are advised to undergo regular blood tests and clinical examinations while taking this medication and to use it safely according to their doctor's instructions.

Side effects

Hypersensitivity reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, itching, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, myasthenia gravis, cough, difficulty breathing, diarrhea, oculomotor weakness, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms syndrome, lichenoid drug eruption, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, increased ALT, chest pain, muscle cramps, gout, erectile dysfunction, numbness, paresthesia, chest discomfort, loss of appetite, abdominal distension, abnormal liver function tests, syncope, generalized pain, fatigue

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture. It is best to maintain a storage temperature between 1 and 30 degrees Celsius room temperature. This helps to preserve the medication's effectiveness and safety for an extended period.

Appearance and packaging

Appearance

Yellow round film-coated tablet

Package unit

For domestic use - 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.